CClinicalTrials.gg
Status unknownNCT04622202Updated Feb 4, 2021

Pre-emptive Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section

A Phase 1/2 interventional study of Pregabalin 150mg and multivitamin in Anxiety State and Sedation, sponsored by Zagazig University. Status unknown at 1 site in Egypt. Open to female participants aged 21 Years to 38 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Zagazig University · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
21 Years to 38 Years
Sex
Female
01

Study summary

There is exaggerated neuroendocrine stress response to laryngoscopy and endotracheal intubation during the Induction to anesthesia-delivery (I-D) period under light anesthesia. Mechanical stimulation of laryngeal proprioceptors elicits increased secretion of cortisol and catecholamine with subsequent elevation of blood pressure from 40 to 50 % and heart rate up to 20 % during direct laryngoscopy and endotracheal intubation

Read the detailed description

The sample size was calculated using OPEN EPI program assuming that the mean visual analogue scale anxiety score was 49.3±14.1 among oral pregabalin group and was 58.6± 14.4 among Placebo group (8) so at power of study 80% confidence interval 95%, the sample size was calculated to be 74 cases (37in each group

02

Conditions studied

  • Anxiety State
  • Sedation

Browse trials for

03

In context

Anxiety Disorders

4,874 studies on the registry are indexed under Anxiety Disorders; 1,394 are open to participants now.

This study's planned enrollment of 74 is close to the median of 80 across 4,180 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: 21-38 years old.
  • Pregnant Female with a singleton fetus of at least 36 weeks of gestation.
  • American Society of Anesthesiologist Physical status: 1\& II.
  • Body Mass Index (BMI) (25-30kg/m²).
  • Type of operations: elective caesarean section under general anesthesia.
  • Written informed consent from the parturient.

Exclusion criteria

Exclusion Criteria:

  • Altered mental state.
  • Women with known history of allergy to pregabalin.
  • Women with uncontrolled diabetes mellitus, bleeding, coagulation disorders, Hepatic, renal, Cardiovascular, respiratory disease and neuropsychiatric disorders.
  • Patients receiving anticonvulsants, antidepressants.
  • Pregnancy induced hypertension, intrauterine growth restriction or fetal compromise
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Active comparator
    pregabalin

    oral capsule pregabalin 150 mg.

    Drug: Pregabalin 150mg

  • Placebo comparator
    multivitamin

    oral multivitamin capsule.

    Drug: multivitamin

Interventions

  • DrugPregabalin 150mg

    oral capsule pregabalin 150 mg.

    Also known as: Lyrica

  • Drugmultivitamin

    oral placebo in the form of oral multivitamin capsule.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. preoperative maternal anxiety changes

    Anxiety by State-Trait Anxiety Inventory (STAI) questionnaire before drug administration and 60 minutes after giving drug (pre-induction).

    Time frame: change from baseline at 60 minutes after giving drug preoperative.

Secondary outcomes

  1. Number of participant with changes in level of consciousness

    changes in level of consciousness of participant by Alert, verbal response, pain response and unresponsive (AVPU) scale 60 minutes after giving drug (pre-induction). Alert: The patient is aware of the examiner and can respond to the environment around them on their own. The patient can also follow commands, open their eyes spontaneously, and track objects. Verbally Responsive: The patient's eyes do not open spontaneously. The patient's eyes open only in response to a verbal stimulus directed toward them. The patient is able to react to that verbal stimulus directly and in a meaningful way. Painfully Responsive: The patient's eyes do not open spontaneously. The patient will only respond to the application of painful stimuli by an examiner. The patient may move, moan, or cry out directly in response to the painful stimuli. Unresponsive: The patient does not respond spontaneously. The patient does not respond to verbal or painful stimuli.

    Time frame: at 60 minutes preoperative

  2. Heart rate

    Heart rate will be recorded preoperative baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.

    Time frame: at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.

  3. mean arterial blood pressure

    mean arterial blood pressure

    Time frame: at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.

  4. Serum glucose

    Serum glucose level will be recorded preoperative and at 10 minutes after intubation.

    Time frame: preoperative and at 10 minutes after intubation.

  5. cortisol level

    cortisol level will be recorded preoperative and at 10 minutes after intubation.

    Time frame: preoperative and at 10 minutes after intubation.

  6. Baby Apgar score

    Apgar score at 1 and 5 min after delivery Apgar Scoring Apgar Sign 2 1 0 Appearance (skin color) Normal color all over (hands and feet are pink) Normal color (but hands and feet are bluish) Bluish-gray or pale all over Pulse (heart rate) Normal (above 100 beats per minute) Below 100 beats per minute Absent (no pulse) Grimace ("reflex irritability") Pulls away, sneezes, coughs, or cries with stimulation Facial movement only (grimace) with stimulation Absent (no response to stimulation) Activity (muscle tone) Active, spontaneous movement Arms and legs flexed with little movement No movement, "floppy" tone Respiration (breathing rate and effort) Normal rate and effort, good cry Slow or irregular breathing, weak cry Absent (no breathing) A baby who scores a 7 or above on the test is considered in good health.

    Time frame: at 1 and 5 minutes after delivery

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04622202
Lead sponsor
Zagazig University
Responsible party
Sara mohamed Abdelnaby (lecturer of anaesthesia and surgical intensive care, Zagazig University) — Principal investigator
First posted
Nov 9, 2020
Start date
Nov 15, 2020
Primary completion
Feb 28, 2021 (estimated)
Completion
Mar 1, 2021 (estimated)
Last update
Feb 4, 2021

Study contacts

Sara Abdel Naby, M.D
Contact
sara.abdelnaby.ali@gmail.com
01096017090 ext. 002
Alshaimaa kamel, M.D
Contact
AlshaimaaKamel80@yahoo.com
01005593169 ext. 002
Sara Abdel Naby, M.D
principal investigator · Zagazig University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion